Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of “Moderate Buy” by Analysts

Absci Corporation (NASDAQ:ABSI) has been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $12.5714.

A number of research analysts have issued reports on the stock. BTIG Research upped their target price on shares of Absci from $9.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners began coverage on shares of Absci in a report on Thursday, June 4th. They issued an “outperform” rating and a $12.00 price objective on the stock. HC Wainwright raised their price objective on shares of Absci from $8.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price (up from $7.00) on shares of Absci in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Absci in a research report on Monday, April 20th.

Absci Stock Up 1.4%

ABSI stock opened at $10.21 on Friday. Absci has a twelve month low of $2.24 and a twelve month high of $11.25. The company has a market cap of $1.59 billion, a P/E ratio of -12.30 and a beta of 2.44. The business has a fifty day moving average of $5.80 and a 200-day moving average of $4.01.

Absci (NASDAQ:ABSI) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $1.39 million. Absci had a negative return on equity of 66.32% and a negative net margin of 6,450.76%. As a group, equities research analysts anticipate that Absci will post -0.72 earnings per share for the current fiscal year.

Key Stories Impacting Absci

Here are the key news stories impacting Absci this week:

• Positive Sentiment: Absci reported positive interim Phase 1 data for ABS-201 in its HEADLINE trial, saying the drug was well tolerated across single-ascending-dose cohorts with no serious adverse events and a long estimated half-life that could support infrequent dosing. Article: Absci Announces Positive Interim Phase 1 Data from the HEADLINE Trial of ABS-201
• Positive Sentiment: The company said the data advanced the study into the multiple-ascending-dose phase, keeping the ABS-201 hair-loss program on track for additional proof-of-concept readouts later in 2026 and early 2027. Article: ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
• Positive Sentiment: Absci also priced a $100 million underwritten offering, with participation from Eli Lilly and other institutional investors, providing capital to fund ABS-201 development across androgenetic alopecia and endometriosis. Article: Absci Announces Pricing of $100 Million Underwritten Offering
• Neutral Sentiment: Analyst updates were mixed but generally supportive, with Needham and BTIG both reiterating buy ratings and raising price targets, which may help reinforce the recent momentum in ABSI shares.
• Neutral Sentiment: Absci reached a new 52-week high and saw heavy trading volume, suggesting the stock’s move is being driven by strong investor reaction to the clinical and financing news.
• Negative Sentiment: The share sale introduces dilution, and some commentary noted that further upside may depend on whether later-stage data continues to validate the early encouraging results.

Institutional Investors Weigh In On Absci

Institutional investors have recently made changes to their positions in the stock. State Street Corp increased its holdings in Absci by 190.1% in the fourth quarter. State Street Corp now owns 5,990,877 shares of the company’s stock valued at $20,908,000 after purchasing an additional 3,925,926 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Absci during the fourth quarter worth about $8,201,000. Baker BROS. Advisors LP bought a new position in Absci during the fourth quarter worth about $7,450,000. ARK Investment Management LLC grew its position in shares of Absci by 21.1% during the 3rd quarter. ARK Investment Management LLC now owns 12,162,773 shares of the company’s stock worth $36,975,000 after buying an additional 2,116,845 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Absci by 2,955.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,156,067 shares of the company’s stock worth $7,526,000 after buying an additional 2,085,501 shares during the period. 52.05% of the stock is owned by institutional investors and hedge funds.

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.